405 related articles for article (PubMed ID: 10073260)
21. Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience.
Chang JH; Kim DK; Kim HW; Park SY; Yoo TH; Kim BS; Kang SW; Choi KH; Han DS; Jeong HJ; Lee HY
Nephrol Dial Transplant; 2009 Aug; 24(8):2406-10. PubMed ID: 19264742
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study.
Naumovic R; Jovanovic D; Pavlovic S; Stosovic M; Marinkovic J; Basta-Jovanovic G
Biomed Pharmacother; 2011 Mar; 65(2):105-10. PubMed ID: 21109389
[TBL] [Abstract][Full Text] [Related]
23. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
Cagnoli L;
G Ital Nefrol; 2003; 20 Suppl 24():S3-47. PubMed ID: 14666502
[TBL] [Abstract][Full Text] [Related]
24. Cyclosporine in idiopathic nephrotic syndrome.
Ponticelli C
Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):479-89. PubMed ID: 8227973
[TBL] [Abstract][Full Text] [Related]
25. One-center experience with cyclosporine in refractory nephrotic syndrome in children.
Singh A; Tejani C; Tejani A
Pediatr Nephrol; 1999 Jan; 13(1):26-32. PubMed ID: 10100285
[TBL] [Abstract][Full Text] [Related]
26. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.
Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Nitta K; Tsukamoto T; Uchida S; Takeda A; Sato T; Wada T; Hayashi H; Akai Y; Fukunaga M; Tsuruya K; Masutani K; Konta T; Shoji T; Hiramatsu T; Goto S; Tamai H; Nishio S; Shirasaki A; Nagai K; Yamagata K; Hasegawa H; Yasuda H; Ichida S; Naruse T; Fukami K; Nishino T; Sobajima H; Tanaka S; Akahori T; Ito T; Yoshio T; Katafuchi R; Fujimoto S; Okada H; Ishimura E; Kazama JJ; Hiromura K; Mimura T; Suzuki S; Saka Y; Sofue T; Suzuki Y; Shibagaki Y; Kitagawa K; Morozumi K; Fujita Y; Mizutani M; Shigematsu T; Kashihara N; Sato H; Matsuo S; Narita I; Isaka Y
Clin Exp Nephrol; 2018 Dec; 22(6):1266-1280. PubMed ID: 29679356
[TBL] [Abstract][Full Text] [Related]
27. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil in primary glomerulopathies.
Sepe V; Libetta C; Giuliano MG; Adamo G; Dal Canton A
Kidney Int; 2008 Jan; 73(2):154-62. PubMed ID: 17989649
[TBL] [Abstract][Full Text] [Related]
29. Primary nephrotic syndrome in Arab children in Kuwait.
Zaki M; Helin I; Manandhar DS; Hunt MC; Khalil AF
Pediatr Nephrol; 1989 Apr; 3(2):218-20; discussion 221. PubMed ID: 2642101
[TBL] [Abstract][Full Text] [Related]
30. What is new in therapy of glomerulonephritis in 2003/2004.
Hruby Z
Rocz Akad Med Bialymst; 2004; 49():166-9. PubMed ID: 15631335
[TBL] [Abstract][Full Text] [Related]
31. Posttransplant recurrence of primary glomerulonephritis.
Ponticelli C; Glassock RJ
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2363-72. PubMed ID: 21030574
[TBL] [Abstract][Full Text] [Related]
32. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases.
Meyrier A
Nephrol Dial Transplant; 1992; 7 Suppl 1():80-4. PubMed ID: 1337187
[No Abstract] [Full Text] [Related]
33. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
Zietse R; Wenting GJ; Kramer P; Schalekamp MA; Weimar W
Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544
[TBL] [Abstract][Full Text] [Related]
34. [Indications for cyclosporin in the treatment of idiopathic nephrotic syndrome in adults].
Zietse R; Weimar W
Ned Tijdschr Geneeskd; 1992 Sep; 136(36):1749-53. PubMed ID: 1407123
[No Abstract] [Full Text] [Related]
35. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
36. [Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)].
Podracká L; Matoušovic K
Vnitr Lek; 2013 Feb; 59(2):113-8. PubMed ID: 23461400
[TBL] [Abstract][Full Text] [Related]
37. The changing pattern of glomerulonephritis in Singapore over the past two decades.
Woo KT; Chiang GS; Pall A; Tan PH; Lau YK; Chin YM
Clin Nephrol; 1999 Aug; 52(2):96-102. PubMed ID: 10480220
[TBL] [Abstract][Full Text] [Related]
38. Is cyclosporine A safe in IgA nephropathy and nephrotic syndrome?
Révai T; Harmos G
Clin Nephrol; 1999 Jul; 52(1):66. PubMed ID: 10442503
[No Abstract] [Full Text] [Related]
39. Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis.
Cattran DC
Clin Nephrol; 1991; 35 Suppl 1():S43-7. PubMed ID: 1860267
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study.
Goumenos DS; Tsagalis G; El Nahas AM; Shortland JR; Davlouros P; Vlachojannis JG; Brown CB
Nephron Clin Pract; 2006; 104(2):c75-82. PubMed ID: 16785738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
